Midterm MRI Follow-Up of Untreated Enchondroma and Atypical Cartilaginous Tumors in the Long Bones

• Published in: Cancers Vol. 13; no. 16; p. 4093
• Main Authors: Deckers, Claudia, Rooy, Jacky W. J. de, Flucke, Uta, Schreuder, H. W. Bart, Dierselhuis, Edwin F., Geest, Ingrid C. M. van der
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 13.08.2021; MDPI
• Subjects: Arthritis; Bone cancer; Bone tumors; Bones; Calcification; Chondrosarcoma; Magnetic resonance imaging; Pain; Patients; Surveillance; Tumors
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers13164093

Management of atypical cartilaginous tumors (ACTs) in the long bones is shifting towards active surveillance to avoid unnecessary surgeries. The frequency and duration of active surveillance for these tumors is unclear as there is little knowledge of its biological behavior. In this retrospective study, we examined the natural course of enchondroma and ACTs through active surveillance. A total of 128 central cartilaginous tumors, located in the long bones, with a minimum interval of 24 months between baseline and last MRI were included. MRI characteristics (e.g., size, scalloping, fat entrapment) were scored and tumors were classified according to the changes between MRIs. Mean follow-up of this study was 50 months, range = 25–138 months. The majority of the cartilaginous tumors (87%) remained stable (n = 65) or showed regression (n = 46) on MRI. A total of 87% of the cases that developed tumor regression presented with entrapped fat at diagnosis. Only 13% (n = 17) showed some progression on MRI, although none of the tumors developed characteristics of high-grade chondrosarcoma. Based on our results, active surveillance is considered safe for enchondroma and ACTs of the long bones. We propose active surveillance for all asymptomatic enchondroma or ACTs in the long bones irrespective of tumor size, and follow-up schemes should be tailored on natural course.